PG F2alpha receptor: a promising therapeutic target for cardiovascular disease

Prostaglandins (PGs), a group of key lipid mediators, are involved in numerous physiological and pathological processes including inflammation and cardiovascular homeostasis. Each PG acts on its specific and distinct cell surface G protein coupled receptors (GPCR) or peroxisome proliferator-activate...

Full description

Bibliographic Details
Main Authors: Jian Zhang, Yanjun Gong, Ying Yu
Format: Article
Language:English
Published: Frontiers Media S.A. 2010-10-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fphar.2010.00116/full
id doaj-eff1d138bf094974b28147434379a076
record_format Article
spelling doaj-eff1d138bf094974b28147434379a0762020-11-24T21:18:35ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122010-10-01110.3389/fphar.2010.001161871PG F2alpha receptor: a promising therapeutic target for cardiovascular diseaseJian Zhang0Yanjun Gong1Ying Yu2Chinese Academy of SciencesChinese Academy of SciencesChinese Academy of SciencesProstaglandins (PGs), a group of key lipid mediators, are involved in numerous physiological and pathological processes including inflammation and cardiovascular homeostasis. Each PG acts on its specific and distinct cell surface G protein coupled receptors (GPCR) or peroxisome proliferator-activated receptors (PPARs). Prostaglandin F2aphar receptor (FP) is required for female reproductive function such as luteolysis and parturition. It has recently been implicated in blood pressure regulation, atherosclerosis and other inflammation-related disorders. The emerging role of FP in cardiovascular diseases is highlighted and potential therapeutic translation is discussed in the current review.http://journal.frontiersin.org/Journal/10.3389/fphar.2010.00116/fullAtherosclerosisHypertensionFP receptorProstaglandin F2alphar
collection DOAJ
language English
format Article
sources DOAJ
author Jian Zhang
Yanjun Gong
Ying Yu
spellingShingle Jian Zhang
Yanjun Gong
Ying Yu
PG F2alpha receptor: a promising therapeutic target for cardiovascular disease
Frontiers in Pharmacology
Atherosclerosis
Hypertension
FP receptor
Prostaglandin F2alphar
author_facet Jian Zhang
Yanjun Gong
Ying Yu
author_sort Jian Zhang
title PG F2alpha receptor: a promising therapeutic target for cardiovascular disease
title_short PG F2alpha receptor: a promising therapeutic target for cardiovascular disease
title_full PG F2alpha receptor: a promising therapeutic target for cardiovascular disease
title_fullStr PG F2alpha receptor: a promising therapeutic target for cardiovascular disease
title_full_unstemmed PG F2alpha receptor: a promising therapeutic target for cardiovascular disease
title_sort pg f2alpha receptor: a promising therapeutic target for cardiovascular disease
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2010-10-01
description Prostaglandins (PGs), a group of key lipid mediators, are involved in numerous physiological and pathological processes including inflammation and cardiovascular homeostasis. Each PG acts on its specific and distinct cell surface G protein coupled receptors (GPCR) or peroxisome proliferator-activated receptors (PPARs). Prostaglandin F2aphar receptor (FP) is required for female reproductive function such as luteolysis and parturition. It has recently been implicated in blood pressure regulation, atherosclerosis and other inflammation-related disorders. The emerging role of FP in cardiovascular diseases is highlighted and potential therapeutic translation is discussed in the current review.
topic Atherosclerosis
Hypertension
FP receptor
Prostaglandin F2alphar
url http://journal.frontiersin.org/Journal/10.3389/fphar.2010.00116/full
work_keys_str_mv AT jianzhang pgf2alphareceptorapromisingtherapeutictargetforcardiovasculardisease
AT yanjungong pgf2alphareceptorapromisingtherapeutictargetforcardiovasculardisease
AT yingyu pgf2alphareceptorapromisingtherapeutictargetforcardiovasculardisease
_version_ 1726008375833001984